Volume 34, Issue 8 (November 2023)
Studies in Medical Sciences 2023, 34(8): 461-470 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khorramnia S, Jalili M, Salajegheh M, Mansouri M. EFFICACY OF BAMLANIVIMAB COMPARED TO STANDARD CARE IN TREATMENT OF THE PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS. Studies in Medical Sciences 2023; 34 (8) :461-470
URL: http://umj.umsu.ac.ir/article-1-6027-en.html
URL: http://umj.umsu.ac.ir/article-1-6027-en.html
MSc, School of Management and Medical Informatics, Kerman University of Medical Sciences, Kerman, Iran (Corresponding Author) , mohsen3893@gmail.com
Abstract: (843 Views)
Background & Aims: Bamlanivimab is a monoclonal antibody for the treatment of mild to moderate cases of Coronavirus disease 2019 (COVID-19). The aim of the current meta-analysis review study was to compare the efficacy of bamlanivimab and standard treatment in the treatment of patients with Covid-19.
Materials & Methods: PubMed, Scopus, Cochrane Library and Web of Science databases were searched to identify relevant articles from 2020 to 2023. Also, a manual search was performed in the sources of primary review and key studies. There were no restrictions on the language of the studies. Evaluation of the quality of studies was done with the Newcastle tool. Data analysis was done using Review Manager software version 5.4.
Results: In total, 16 studies including 23166 covid-19 patients were included in the study. The results of the meta-analysis showed that a significant difference was observed between the bamlanivimab and standard care groups in terms of mortality rate (odds ratio [OR] = 0.26, confidence interval [CI]: 0.17 to 0.42, P>0.001), hospitalization rate (OR= 0.45; 95% CI: 0.31 to 0.66, P>0.001), and ICU admission (OR= 0.39; 95% CI: 0.21 to 0.72, P=0.003).
Conclusion: According to evidence from the current review, bamlanivimab reduces mortality, risk of hospitalization, and intensive care unit (ICU) admission in the patients with mild or moderate Covid-19. The results of this study can help health policy makers in choosing effective treatments for Covid-19 patients.
Materials & Methods: PubMed, Scopus, Cochrane Library and Web of Science databases were searched to identify relevant articles from 2020 to 2023. Also, a manual search was performed in the sources of primary review and key studies. There were no restrictions on the language of the studies. Evaluation of the quality of studies was done with the Newcastle tool. Data analysis was done using Review Manager software version 5.4.
Results: In total, 16 studies including 23166 covid-19 patients were included in the study. The results of the meta-analysis showed that a significant difference was observed between the bamlanivimab and standard care groups in terms of mortality rate (odds ratio [OR] = 0.26, confidence interval [CI]: 0.17 to 0.42, P>0.001), hospitalization rate (OR= 0.45; 95% CI: 0.31 to 0.66, P>0.001), and ICU admission (OR= 0.39; 95% CI: 0.21 to 0.72, P=0.003).
Conclusion: According to evidence from the current review, bamlanivimab reduces mortality, risk of hospitalization, and intensive care unit (ICU) admission in the patients with mild or moderate Covid-19. The results of this study can help health policy makers in choosing effective treatments for Covid-19 patients.
Type of Study: Review article |
Subject:
ویروس شناسی
References
1. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19(3):141-54. [DOI:10.1038/s41579-020-00459-7] [PMID] []
2. Ahorsu DK, Lin C-Y. The effect of COVID-19 vaccine acceptance, intention, and/or hesitancy and its association with our health and/or important areas of functioning. Vaccines (Basel) 2023;11(2). [DOI:10.3390/vaccines11020368] [PMID] []
3. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022;22(9):1293-302. [DOI:10.1016/S1473-3099(22)00320-6] [PMID]
4. Marks PW, Gruppuso PA, Adashi EY. Urgent need for next-generation COVID-19 vaccines. JAMA 2023;329(1):19-20. [DOI:10.1001/jama.2022.22759] [PMID]
5. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021;384(3):238-51. [DOI:10.1056/NEJMoa2035002] [PMID] []
6. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 2020;324(2):131-2. [DOI:10.1001/jama.2020.10245] [PMID]
7. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med 2021;13(593):eabf1906. [Google Scholar]
8. Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, et al., editors. Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19. Open forum infectious diseases; 2021: Oxford University Press US. [DOI:10.1093/ofid/ofab331] [PMID] []
9. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021;384(3):229-37. [DOI:10.1056/NEJMoa2029849] [PMID] []
10. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N Engl J Med 2021;385(15):1382-92. [DOI:10.1056/NEJMoa2102685] [PMID] []
11. Alam MM, Mahmud S, Aggarwal S, Fathma S, Al Mahi N, Shibli MS, et al. Clinical impact of the early use of monoclonal antibody LY-CoV555 (bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study. Cureus 2021;13(5). [DOI:10.7759/cureus.14933]
12. Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, et al., editors. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection. Open forum infectious diseases; 2021: Oxford University Press US. [DOI:10.1093/ofid/ofab254] [PMID] []
13. Brock P, Dagher H, Wechsler AH, Lipe DN, Chaftari P, Chaftari A-M, et al., editors. 542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19. Open Forum Infectious Diseases; 2021: Oxford University Press. [DOI:10.1093/ofid/ofab466.741] []
14. Cooper MH, Christensen PA, Salazar E, Perez KK, Graviss EA, Nguyen D, et al., editors. Real-world assessment of 2879 COVID-19 patients treated with monoclonal antibody therapy: a propensity score-matched cohort study. Open forum infectious diseases; 2021: Oxford University Press US. [DOI:10.1093/ofid/ofab512] [PMID] []
15. Corwin DS, Ender PT, Sahu N, Durgham RA, McGorry Jr DM, Rahman A, et al., editors. The efficacy of bamlanivimab in reducing emergency department visits and hospitalizations in a real-world setting. Open Forum Infectious Diseases; 2021: Oxford University Press US. [DOI:10.1093/ofid/ofab305] [PMID] []
16. Destache CJ, Aurit SJ, Schmidt D, Peet Erkes L, Tierney M, Vivekanandan R. Bamlanivimab use in mild‐to‐moderate COVID‐19 disease: a matched cohort design. Pharmacother 2021;41(9):743-7. [DOI:10.1002/phar.2613] [PMID] []
17. Ganesh R, Pawlowski CF, O'Horo JC, Arndt LL, Arndt RF, Bell SJ, et al. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. J Clin Invest 2021;131(19). [DOI:10.1172/JCI151697] [PMID] []
18. Iqbal L, Terlau TJ, Hernandez A, Woods K, Terlau T, Hernandez AT. Efficacy of bamlanivimab in reducing hospitalization and mortality rates in COVID-19 patients in a rural community. Cureus 2021;13(7). [DOI:10.7759/cureus.16477]
19. Koehler J, Ritzer B, Weidlich S, Gebhardt F, Kirchhoff C, Gempt J, et al. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. Infection 2021;49(6):1313-8. [DOI:10.1007/s15010-021-01657-y] [PMID] []
20. Rubin EB, Boiarsky JA, Canha LA, Giobbie-Hurder A, Liu M, Townsend MJ, et al., editors. Bamlanivimab efficacy in older and high-BMI outpatients with COVID-19 selected for treatment in a lottery-based allocation process. Open Forum Infectious Diseases; 2021: Oxford University Press US. [DOI:10.1093/ofid/ofab546] [PMID] []
21. Djuric P, Bogicevic J, Pešić S, Davidovic Z, Naumovic R. First experience of bamlanivimab for covid-19 positive haemodialysis patients: A case-control study. Nephrol Dial Transplant 2022:i481-i2. [DOI:10.1093/ndt/gfac077.019] []
22. Karr E, Chung T, Burtson K, Markert R, Kelly D. Bamlanivimab use in a military treatment facility. Mil Med 2022;187(11-12):e1261-e4. [DOI:10.1093/milmed/usab188] [PMID] []
23. Kumar RN, Wu E-L, Stosor V, Moore WJ, Achenbach C, Ison MG, et al. Real-world experience of bamlanivimab for Coronavirus Disease 2019 (COVID-19): a case-control study. Clin Infect Dis 2022;74(1):24-31. [DOI:10.1093/cid/ciab305] [PMID] []
24. Murillo M, Lomiguen C, Terrell M, King A, Lin J, Ferretti S. Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents. Aging Dis 2022;13(5). [DOI:10.14336/AD.2022.0205] [PMID] []
25. Quenzer FC, Lafree AT, Grey L, Singh S, Smyers C, Balog B, et al. Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals. West J Emerg Med 2022;23(3):302. [DOI:10.5811/westjem.2021.10.52668] [PMID] []
26. Sridhara S, Gungor AB, Erol HK, Al-Obaidi M, Zangeneh TT, Bedrick EJ, et al. Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 subvariants dominated era. Plos One 2023;18(4):e0279326. [DOI:10.1371/journal.pone.0279326] [PMID] []
27. Peterson J, Welch V, Losos M, Tugwell PJOOHRI. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hosp Res Instit 2011;2(1):1-12. [URL]
28. Zuo L, Ao G, Wang Y, Gao M, Qi X. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: a systematic review and meta-analysis. J Infect 2022;84(2):248-88. [DOI:10.1016/j.jinf.2021.09.003] [PMID] []
29. Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, et al. A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2. Infect Dis Ther 2021;10(4):1933-47. [DOI:10.1007/s40121-021-00515-6] [PMID] []
30. Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis. Rev Med Virol 2022;32(6):e2402. [DOI:10.1002/rmv.2402] [PMID] []
31. Xiang Hr, He B, Li Y, Cheng X, Zhang Qz, Peng Wx. Bamlanivimab plus etesevimab treatment have a better outcome against COVID‐19: A meta‐analysis. J Med Virol 2022;94(5):1893-905. [DOI:10.1002/jmv.27542] [PMID]
32. Yang M, Li A, Wang Y, Tran C, Zhao S, Ao G. Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: a meta-analysis. J Infect 2022;85(4):436-80. [DOI:10.1016/j.jinf.2022.06.027] []
33. Luo J, Li A, Liu C, Wang Y, Tran C, Ao G. The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis. J Infect 2023. [DOI:10.1016/j.jinf.2023.04.010] [PMID] []
34. Gao M, Ao G, Hao X, Xie B. Casirivimab-Imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis. J Infect 2023. [DOI:10.1016/j.jinf.2023.04.019] [PMID] []
35. McCreary EK, Kip KE, Collins K, Minnier TE, Snyder GM, Steiner A, et al., editors. Evaluation of bebtelovimab for treatment of Covid-19 during the SARS-CoV-2 Omicron variant era. Open Forum Infectious Diseases; 2022: Oxford University Press US. [DOI:10.1093/ofid/ofac517] [PMID] []
36. Bown M, Sutton A. Quality control in systematic reviews and meta-analyses. Eur J Vasc Endovasc Surg 2010;40(5):669-77. [DOI:10.1016/j.ejvs.2010.07.011] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
